The Indian Challenge: The Evolution of a Successful New Global Strategy in the Pharmaceutical Industry

Abstract UK and European public policy has sought to encourage young biotechnology firms adopt American-inspired strategies. The venture-backed start-up associated with Silicon Valley and Route 128 in Boston, has been the preferred model. These policies have had limited success thus far. Indian companies are evolving indigenous business models that are achieving success within the pharmaceutical industry. Some Indian pharmaceutical firms, established initially as low cost suppliers, are investing in building innovative capabilities. This paper analyses the strategies and trajectories of a number of Indian pharmaceutical companies that are expanding successfully in Western markets. It assesses the local and international contextual factors that have underpinned the strategies and discusses relevant conceptual frameworks.

[1]  V. Chiesa,et al.  Network of Collaborations for Innovation: The Case of Biotechnology , 2004 .

[2]  Daniel A. Levinthal,et al.  ABSORPTIVE CAPACITY: A NEW PERSPECTIVE ON LEARNING AND INNOVATION , 1990 .

[3]  David Wield,et al.  Diffusion of knowledge through migration of scientific labour in India , 2008 .

[4]  J. Lanjouw.  The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"? , 1997 .

[5]  David B. Audretsch,et al.  The Role of Small Firms in U.S. Biotechnology Clusters , 2001 .

[6]  Balaji R. Koka,et al.  Strategic alliances as social capital: a multidimensional view , 2002 .

[7]  A. Saxenian,et al.  The Limits of Guanxi Capitalism: Transnational Collaboration between Taiwan and the USA , 2000 .

[8]  D. Leonard-Barton.  CORE CAPABILITIES AND CORE RIGIDITIES: A PARADOX IN MANAGING NEW PRODUCT DEVELOPMENT , 1992 .

[9]  Tse-Kang Leng,et al.  Economic Globalization and it Talent Flows Across the Taiwan Strait: The Taipei/Shanghai/Silicon Valley Triangle , 2002 .

[10]  Gary P. Pisano,et al.  The Development Factory: Unlocking the Potential of Process Innovation , 1996 .

[11]  Carl E. Pray,et al.  Public-Private Sector Linkages in Research and Development: Biotechnology and the Seed Industry in Brazil, China and India , 2001 .

[12]  E. Barozet,et al.  Social Capital. A Theory of Social Structure and Action , 2002 .

[13]  C. Lévi-Strauss.  The Savage Mind , 1967 .

[14]  T. Kostova,et al.  Social Capital in Multinational Corporations and a Micro-Macro Model of its Formation , 2003 .

[15]  C. Fink.  Patent Protection, Transnational Corporations, and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry , 2001 .

[16]  Robert T. Keller,et al.  A RESOURCE-BASED STUDY OF NEW PRODUCT DEVELOPMENT: PREDICTING FIVE-YEAR LATER COMMERCIAL SUCCESS AND SPEED TO MARKET , 2004 .

[17]  George S. Day,et al.  Driving Through the Fog: Managing at the Edge , 2004 .

[18]  David B. Audretsch,et al.  The role of small firms in US biotechnology clusters , 2003 .

[19]  Rebecca Henderson,et al.  Sources of Industrial Leadership: The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change , 1999 .

[20]  C. Prahalad.  The Blinders of Dominant Logic , 2004 .

[21]  Anne S. Miner,et al.  Improvising firms: bricolage, account giving and improvisational competencies in the founding process , 2003 .

[22]  Mark Dodgson,et al.  Strategic Research Partnerships: Empirical Evidence from Asia , 2003, Technol. Anal. Strateg. Manag..

[23]  Mark S. Granovetter.  The Strength of Weak Ties , 1973, American Journal of Sociology.

[24]  S. Ramani.  Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms , 2002 .

[25]  B. Kogut,et al.  Knowledge of the Firm, Combinative Capabilities, and the Replication of Technology , 1992 .